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Fibrin degradation products in renal disease. A. R. Clarkson,
M. K. MacDonald, A. M. Davison, J. D. Cash, and J. S. Robson,
Medical Renal Unit, Royal Infirmary, Edinburgh, Scotland. The
proteolysis of fibrin and fibrinogen by the fibrinolytic enzyme
plasmin gives rise to degradation products (F. D. P.) of known
molecular size, immunological and anticoagulant properties and
electron microscopic appearances. Fragments X and Y are
intermediate degradation products while D and E are plasmin
resistant. All may combine with fibrinogen in the circulation to
form soluble high molecular weight complexes which may be
dissociated with paracoagulating agents. In serum and urine of
the patients with renal disease the measurement of F. D. P. by
the Tanned Red Cell Haemagglutination Inhibition Immuno-
assay (TRCFIII) has been preferred to the Staphylococcal
Clumping Test (S. C. T.) and other methods because of its
greater sensitivity and its ability to detect fragments D and E.
Results of daily serum and urinary F. D. P. assays have been
correlated with clinical features and histopathological, immuno-
fluorescent and electron microscopic appearances of renal
biopsies in a wide variety of renal diseases. In acute ischaemic
renal failure, persistently elevated serum F. D. P. concentrations
during the oliguric phase which return to normal values at the
time of recovery, coupled with the electron microscopic finding
of thrombosis in glomerular capillaries and a flushing out of
F. D. P. into the urine during recovery suggests that coagulation
may play a part in the pathogenesis of this disease. In proliferative
forms of glomerulonephritis and renal homograft rejection the
measurement of serum F. D. P. does not reliably reflect intra-
renal events. On the other hand, serial assay of urine F. D. P.
concentration has provided a reliable and sensitive assessment
of disease severity, activity, natural history and response to
therapy with anti-inflammatory and anti-coagulant drugs. The
use of the TRCHII to measure urine F. D. P. concentration in
these conditions is, therefore, of potential value.
Erythropoietin: The present status. P. Mary Cotes, M. R. C.,
Mill Hill, London. Disorder of the erythropoietin mechanism for
homeostasis of red cell production is seen clinically as over-
production (in association with certain tumors), under-production
(in association with some renal lesions) and as end-organ un-
responsiveness (in polycythaemia rubra vera). Recent advances
in knowledge of the erythropoietin system include further puri-
fication of the hormone from human urine and from sheep
plasma; characterization of the sheep hormone as a glycoprotein,
M.W. 45,800 and recognition of interacting plasma and renal
precursors of the hormone. Physiological studies have been
hampered by the insensitivity of bioassays for erythropoietin.
In Vitro assay systems using cultures of haemopoietic tissues are
sensitive to interference by some non-erythropoietin constituents
in body fluids and have not proved applicable to assay of erythro-
poietin in plasma. Other laboratories have set up a red cell
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haemagglutination inhibition assay for erythropoietin and are
attempting to develop radioimmunoassays for the hormone.
We have developed a radioimmunoassay for an erythropoietin-
like constituent of sheep plasma which, like biologically active
erythropoietin in plasma, is increased following induction of
anaemia by bleeding. It is hoped to extend application of this
system to estimation of the human hormone.
Paraproteins and the kidney. J. R. Hobss, Westminster Medical
School, London, England. In the associated age group a blood
urea above 80 mg/I00 ml and albuminuria (as distinct from
paraproteinuria) above 10 mg/100 ml (emphasizing the value of
urine electrophoresis) have been sure signs of renal failure in the
numerous patients followed in the M.R.C. Myeloma trials.
1. Hypercalcaemia (45% patients) is not always cortisone sup-
pressible, is aggravated by bed rest or a fluid intake below 6
pints daily, can respond rapidly to intravenous cytotoxics and
with current management no longer carries a worse prognosis.
2. Pyelonephritis (30% patients) may be due to impaired bacteri-
cidal action subsequent to low serum 1gM. 3. Myeloma kidney,
in only 15% patients despite Bence Jones proteinuria in 80%,
is unrelated to the amount of paraproteinuria, to K/L typing and
can be precipitated by IVP procedures. 4. Amyloid (10% patients),
deposition of V-portions of light chains, is best diagnosed by
renal biopsy and electron microscopy can reveal typical fibrils
despite negative results from usual stains. While cytotoxics have
shown biopsy reversion in children with Still's disease, in our
adults only arrest of deposition is as yet accredited. Progress of
deposition can mislead by actually decreasing proteinuria. 5,
"Minimal lesion" nephrosis (2% patients, EM negative for amy-
bid). As the tumor was poisoned, and the paraprotein level
reduced, so was the proteinuria. With relapse of the tumor and
its paraprotein, nephrosis recurred. 6. Myelomatous invasion
of the kidney (10% patients), especially occurs with Bence
Jones only or IgD myelomata. 7. Hyperuricaemia (<1%
patients) above 13 mg/100 ml has not yet been detected despite
intensive cytotoxic treatment, probably because of the mostly
slow growth rate (only involving 2 to 6% of tumor cells).
8. Fanconi syndrome (<1% patients) can be clearly acquired
with Bence Jones proteinuria. 9. Viscosity syndrome and cryo-
globulinaemia (5% patients) are both aggravated by the afferent/
efferent glomerular loss of water in that both syndromes are
worse with increased protein levels. Renal failure of an anoxic
type is common and is initially reversible by plasmaphoresis.
10. Such treatment can also reverse renal failure associated with
paraproteinaemia (2% patients, yet independent of causes ito 9),
especially of the IgA class, and can allow a patient time to re-
spond to cytotoxic drugs. 11. Apparent hyponatraemia (4%
patients), is due to hyperparaproteinaemia (IgG> 6g/lOO ml)
mainly displacing plasma water and with some binding of anions.
Mistaken infusion of 1.8% NaCI can kill the patient, who,al-
Abstracts 429
ready has a viscosity syndrome. Over one-third of patients with
paraproteinaemia used to die of renal failure, with causes 3, 4, 8,
9 and 11 directly due to the paraprotein, and causes 1, 2, 6 and 7
due to the associated tumor. With cytotoxic treatment and pre-
ventive care less than 15% do today, but 10% presenting with
irreversible renal failure die in the first six weeks.
The oxygen dissociation curve. E. R. Huehns, University
College Hospital Medical School, London, England. One of the
ways in which oxygen delivery to the tissues can be controlled
is by changes in the position of the oxygen dissociation curve;
in particular, a lowered oxygen affinity causes a greater release
of oxygen from haemaglobin. Recently, it has been shown that
the glycolytic intermediate, 2,3 diphosphoglycerate (2,3-DPG),
plays an important part in the control of oxygen affinity of the
red cell, an increase in red cell 2,3-DPG causing a decrease in
oxygen affinity. The most important physiological effect of 2,3-
DPG is in the determination of the oxygen affinity difference
between adult and foetal blood. This is brought about by a dif-
ference in the interaction of DPG with Hb-F and Hb-A. Two
pathological conditions cause changes in the red cell 2,3-DPG:
tissue hypoxia and alteration in pH. In anaemia, 2,3-DPG in the
red cell rises and the concomitant fall in oxygen affinity increases
the proportion of oxygen released to the tissues. A fall of pH
in the red cell lowers the DPG and the rise in oxygen affinity
approximately balances the change in oxygen affinity caused by
the Bohr shift, and the in vivo oxygen affinity curve remains
normal. However, as the effect of a change of pH on the oxygen
affinity is immediate and any alteration in 2,3-DPG takes about
24 hours to be complete, rapid changes in pH by treatment can
raise the oxygen affinity sufficiently to cause a greatly diminished
supply of oxygen to the tissues. In conditions where there is both
hypoxia and acidosis, such as respiratory or renal disease, the
rise in DPG expected due to hypoxia will be diminished by the
acidosis. However, as the effect on the in vivo oxygen dissociation
curve of DPG and the Bohr effect are additive, the in vivo oxygen
affinity will be low, giving some compensation for the hypoxia
present.
Iron metabolism in kidney failure. Allan Jacobs, University
Hospital of Wales, Cardiff The changes in iron metabolism in
patients with renal failure may be related either to iron balance
or to the distribution of iron within the body. An increase in
body iron usually follows blood transfusion and decreases are
often due to the high rate of loss associated with dialysis. Some
observers have found iron absorption to be impaired. The usual
parameters of iron status may be difficult to interpret in patients
with renal failure. Marrow function is reduced with a consequent
decrease in erythrocyte iron turnover but the extent to which this
is seen depends on erythropoietin levels, iron status and the
presence of haemolysis. Reticuloendothelial metabolism is also
abnormal so that there is impaired release of iron derived from
haemoglobin catabolism and a consequent reduction in supply to
the marrow. There is apparently no increase in ineffective erythro-
poiesis. The effect of treatment with regular dialysis is debatable.
Some groups have shown improvements in erythropoiesis but
the mechanism for this is far from clear.
Diffuse intravascular coagulation. A. A. Sharp, Radcliffe
Infirmary, Oxford, England. The term "diffuse intravascular
coagulation" or "consumptioncoagulopathy" is difficult to define
as one specific entity or syndrome. Today there is a growing
awareness that there is an increasing list of clinical syndromes
caused or complicated by the intravascular deposition of solid
material in the microcirculation of arterioles, venules and
capillaries. The material may be platelets, platelets and fibrin,
fibrin by itself or any of the above mixtures mixed with deposited
antigen-antibody complexes. This solid material may be formed
locally or spread widely throughout the body affecting or
damaging one or more organ systems. There are three possible
triggers to this process: the sudden introduction of large amounts
of tissue factors (thromboplastin) into the circulation, bacterial
endotoxin of varying types and antigen-antibody complexes.
When these factors directly or indirectly initiate intravascular
coagulation, the resultant chain reaction can be measured in the
blood by detecting consumption of platelets and certain plasma
coagulation factors which in turn may lead to abnormal bleeding.
Now that it is recognized that this syndrome may develop in
many widely differing clinical states, several major problems
exist. First, what are the minimal criteria for recognition of this
syndrome? Acute episodes present little problem, but chronic
or transient events are difficult to define. Once it is recognized
that D. I. C. has occurred, the clinician is presented with a prob-
lem as to whether the intravascular thrombosis is causing or
complicating a given clinical state and whether it matters. If it
is decided that the D. I. C. does matter, the next and greatest
dilemma exists in relation to therapy. Should supportive or
replacement therapy alone be given or should only the initiating
stimulus be treated e.g., septicaemia? If there is evidence of
significant and continuing fibrin formation, should anticoagulant
therapy be given in addition to the above or should courageous
attempts be made to remove the existing fibrin remembering
that secondary tissue damage is probably irreversible? There is
no one answer to these problems. What may be justified in one
clinical state may be wrong in another. Each clinician encounters
D. I. C. as a sporadic problem and it is becoming obvious that we
cannot solve this situation without a national or even an inter-
national multicentre co-ordinated approach to diagnosis and
therapy.
